DRUG · Unmapped registry intervention
Sequential Icotinib Plus Chemotherapy
Find medicine records ·
Find other trials using this name
Clinical trial
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
NCT02103257
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Icotinib
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedSequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE4
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
EGFR Positive Non-small Cell Lung Cancerunresolved
Adenocarcinomaverified · MONDO: adenocarcinoma
Interventions
Sponsors & collaborators
Betta Pharmaceuticals Co., Ltd.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02103257 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.